Skip to main content

Advertisement

SpringerLink
Log in

Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Faithful tumor mouse models are fundamental research tools to advance the field of immuno-oncology (IO). This is particularly relevant in diseases with low incidence, as in the case of pediatric malignancies, that rely on pre-clinical therapeutic development. However, conventional syngeneic and genetically engineered mouse models fail to recapitulate the tumor heterogeneity and microenvironmental complexity of human pathology that are essential determinants of cancer-directed immunity. Here, we characterize a novel mouse model that supports human natural killer (NK) cell development and engraftment of neuroblastoma orthotopic patient-derived xenograft (O-PDX) for pre-clinical antibody and cytokine testing. Using cytotoxicity assays, single-cell RNA-sequencing, and multi-color flow cytometry, we demonstrate that NK cells that develop in the humanized mice are fully licensed to execute NK cell cytotoxicity, permit human tumor engraftment, but can be therapeutically redirected to induce antibody-dependent cell-mediated cytotoxicity (ADCC). Although these cells share phenotypic and molecular features with healthy controls, we noted that they lacked an NK cell subset, termed activated NK cells, that is characterized by differentially expressed genes that are induced by cytokine activation. Because this subset of genes is also downregulated in patients with neuroblastoma compared to healthy controls, we hypothesize that this finding could be due to tumor-mediated suppressive effects. Thus, despite its technical complexity, this humanized patient-derived xenograft mouse model could serve as a faithful system for future testing of IO applications and studies of underlying immunologic processes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

source of effector cells. Transplanted MISTRG mice (red) are compared with MISTRG (blue) and NSG (grey) mice that received ACT of NK cells from one donor. Among mice receiving chemo-immunotherapy, transplanted MISTRG mice (N = 7) had more significant tumor growth suppression than did MISTRG and NSG mice that received adoptive NK cells with therapy (N = 5 and 6; P = 0.003; one-way ANOVA). No significant differences occurred between these groups treated with chemotherapy (each MISTRG groups N = 6, NSG group N = 5)

Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

ACT:

Adoptive cell transfer

ADCC:

Antibody-dependent cell-mediated cytotoxicity

CAR:

Chimeric antigen receptor

E.T :

Effector-to-target

FACS:

Fluorescence-activated cell sorting

GD2:

Disialoganglioside

GEMM:

Genetically engineered mouse model

GM-CSF:

Granulocyte–macrophage colony-stimulating factor

HLA:

Human leukocyte antigen

HPCs:

Hematopoietic progenitor cells

IL:

Interleukin

IO:

Immuno-oncology

KIR:

Killer-cell immunoglobulin-like receptors

MISTRG:

M-CSFH/hIL-3/GM-CSFh/hSIRPAh/mTPOh/hRag2null/Il2Rγcnull

MITRG:

M-CSFH/hIL-3/GM-CSFh/hTPOh/hRag2null/Il2Rγcnull

NK:

Natural killer

NSG:

NOD/scid/Il2RγcNull

O-PDX:

Orthotopic patient-derived xenograft

scRNA-seq:

Single-cell RNA-sequencing

References

  1. Stewart E, Federico SM, Chen X et al (2017) Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549:96–100. https://doi.org/10.1038/nature23647

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gu Z, Jiang J, Yan Y et al (2017) Evaluation of the correlations between patient-derived xenograft (PDX) model-based mouse trials and cancer patient-based clinical trials. J Clin Oncol 35:e23140-e. https://doi.org/10.1200/JCO.2017.35.15_suppl.e23140

    Article  Google Scholar 

  3. Overwijk WW, Restifo NP (2001) B16 as a mouse model for human melanoma. Curr Protoc Immunol. https://doi.org/10.1002/0471142735.im2001s39

    Article  PubMed  PubMed Central  Google Scholar 

  4. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565–1570. https://doi.org/10.1126/science.1203486

    Article  CAS  PubMed  Google Scholar 

  5. Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, Berns A (2011) A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19:244–256. https://doi.org/10.1016/j.ccr.2010.12.021

    Article  CAS  PubMed  Google Scholar 

  6. Alexandrov LB, Nik-Zainal S, Wedge DC et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421. https://doi.org/10.1038/nature12477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16:2985–2995. https://doi.org/10.1093/emboj/16.11.2985

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kopetz S, Lemos R, Powis G (2012) The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 18:5160–5162. https://doi.org/10.1158/1078-0432.CCR-12-2408

    Article  PubMed  PubMed Central  Google Scholar 

  9. Nguyen R, Moustaki A, Norrie JL, Brown S, Akers WJ, Shirinifard A, Dyer MA (2019) Interleukin-15 enhances anti-GD2 antibody-mediated cytotoxicity in an orthotopic PDX model of neuroblastoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-1045

    Article  PubMed  PubMed Central  Google Scholar 

  10. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A, Manz MG (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304:104–107. https://doi.org/10.1126/science.1093933

    Article  CAS  PubMed  Google Scholar 

  11. Shultz LD, Lyons BL, Burzenski LM et al (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477–6489. https://doi.org/10.4049/jimmunol.174.10.6477

    Article  CAS  PubMed  Google Scholar 

  12. Strowig T, Chijioke O, Carrega P, Arrey F, Meixlsperger S, Ramer PC, Ferlazzo G, Munz C (2010) Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 116:4158–4167. https://doi.org/10.1182/blood-2010-02-270678

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gille C, Orlikowsky TW, Spring B et al (2012) Monocytes derived from humanized neonatal NOD/SCID/IL2Rgamma(null) mice are phenotypically immature and exhibit functional impairments. Hum Immunol 73:346–354. https://doi.org/10.1016/j.humimm.2012.01.006

    Article  CAS  PubMed  Google Scholar 

  14. Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, Manz MG (2013) Human hemato-lymphoid system mice: current use and future potential for medicine. Annu Rev Immunol 31:635–674. https://doi.org/10.1146/annurev-immunol-032712-095921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rongvaux A, Willinger T, Martinek J et al (2014) Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32:364–372. https://doi.org/10.1038/nbt.2858

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Nguyen R, Houston J, Chan WK, Finkelstein D, Dyer MA (2018) The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Cancer Immunol Immunother 67:615–626. https://doi.org/10.1007/s00262-017-2108-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Stewart E, Shelat A, Bradley C et al (2015) Development and characterization of a human orthotopic neuroblastoma xenograft. Dev Biol 407:344–355. https://doi.org/10.1016/j.ydbio.2015.02.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Crinier A, Milpied P, Escaliere B et al (2018) High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice. Immunity 49(971–86):e5. https://doi.org/10.1016/j.immuni.2018.09.009

    Article  CAS  Google Scholar 

  19. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36:411–420. https://doi.org/10.1038/nbt.4096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hafemeister C, Satija R (2019) Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol 20:296. https://doi.org/10.1186/s13059-019-1874-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yang C, Siebert JR, Burns R et al (2019) Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun 10:3931. https://doi.org/10.1038/s41467-019-11947-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH (1986) The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480–4486

    CAS  PubMed  Google Scholar 

  23. Barry WE, Jackson JR, Asuelime GE et al (2019) Activated natural killer cells in combination with anti-GD2 antibody dinutuximab improve survival of mice after surgical resection of primary neuroblastoma. Clin Cancer Res 25:325–333. https://doi.org/10.1158/1078-0432.CCR-18-1317

    Article  CAS  PubMed  Google Scholar 

  24. Nguyen R, Wu H, Pounds S et al (2019) A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. J Immunother Cancer 7:81. https://doi.org/10.1186/s40425-019-0564-6

    Article  PubMed  PubMed Central  Google Scholar 

  25. Nguyen R, Sahr N, Sykes A et al (2020) Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. J Immunother Cancer. https://doi.org/10.1136/jitc-2019-000176

    Article  PubMed  PubMed Central  Google Scholar 

  26. Furman WL, Federico SM, McCarville MB et al (2019) A phase II trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma. Clin Cancer Res 25:6320–6328. https://doi.org/10.1158/1078-0432.CCR-19-1452

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bahrami S, Drablos F (2016) Gene regulation in the immediate-early response process. Adv Biol Regul 62:37–49. https://doi.org/10.1016/j.jbior.2016.05.001

    Article  CAS  PubMed  Google Scholar 

  28. Mace EM, Dongre P, Hsu HT, Sinha P, James AM, Mann SS, Forbes LR, Watkin LB, Orange JS (2014) Cell biological steps and checkpoints in accessing NK cell cytotoxicity. Immunol Cell Biol 92:245–255. https://doi.org/10.1038/icb.2013.96

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Song Y, Rongvaux A, Taylor A et al (2019) A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nat Commun 10:366. https://doi.org/10.1038/s41467-018-08166-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC (2010) AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24:1785–1788. https://doi.org/10.1038/leu.2010.158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Park JR, Kreissman SG, London WB et al (2019) Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 322:746–755. https://doi.org/10.1001/jama.2019.11642

    Article  PubMed  PubMed Central  Google Scholar 

  32. Leung W, Handgretinger R, Iyengar R, Turner V, Holladay MS, Hale GA (2007) Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma. Br J Cancer 97:539–542. https://doi.org/10.1038/sj.bjc.6603913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100. https://doi.org/10.1126/science.1068440

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Asa Karlstrom, Ph.D., for regulatory support; Nisha Badders, Ph.D., ELS, for editing the manuscript; Mitchell J. Weiss, MD Ph.D., for providing HPCs; William E. Janssen, Ph.D., for providing purity data on HPCs; Jennifer Peters, Ph.D., for acquiring images of the stained tumor slides; Thomas Confer for assisting with the ultrasound studies; Merck Sorono and Children's GMP, LLC for providing hu14.18K322A for our studies; and the NCI Biological Resource Branch for providing IL-2 and IL-15. We thank Adeline Crinier, Bertrand Escalier, and Eric Vivier, Ph.D., for providing the biocomputational datasets of healthy controls. This work was supported, in part, by Cancer Center Support (CA21765) from the National Cancer Institute and grants to RN from the Conquer Cancer ASCO Foundation (12822), to WJA from the National Institutes of Health (R50CA211481), and to MAD from the National Institutes of Health (EY014867 and EY018599 and CA168875). This research was supported by Howard Hughes Medical Institute.

Author information

Author notes

  1. Rosa Nguyen and Anand G. Patel have contributed equally.

Authors and Affiliations

  1. Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Rosa Nguyen, Anand G. Patel, Elizabeth A. Stewart & Wayne L. Furman

  2. Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA

    Rosa Nguyen

  3. Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Anand G. Patel, Lyra M. Griffiths, Jason Dapper, Elizabeth A. Stewart, Jim Houston & Michael A. Dyer

  4. Center for In Vivo Imaging and Therapeutics (CIVIT), St. Jude Children’s Research Hospital, Memphis, TN, USA

    Melissa Johnson & Walter J. Akers

Authors
  1. Rosa Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anand G. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lyra M. Griffiths
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jason Dapper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elizabeth A. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jim Houston
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Melissa Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Walter J. Akers
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wayne L. Furman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michael A. Dyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RN designed and conducted all experiments, analyzed and interpreted all data, and drafted and reviewed the manuscript; AGP analyzed and interpreted the scRNA-seq data and reviewed the manuscript; LMG maintained the MISTRG colony and supplied the mice and reviewed the manuscript; EAS maintained the MISTRG colony, conducted murine experiments requested in revisions, reviewed the manuscript; JD maintained the MISTRG colony, conducted murine experiments requested in revisions, reviewed the manuscript; JH performed flow cytometry analysis and reviewed the manuscript; MJ and WJA performed tumor injections and ultrasound-based tumor measurements and reviewed the manuscript; WLF: provided patient samples and clinical data and reviewed the manuscript; MAD generated the hypothesis, designed, funded, supervised the study, interpreted data, and reviewed and edited the draft.

Corresponding author

Correspondence to Rosa Nguyen.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 1809 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nguyen, R., Patel, A.G., Griffiths, L.M. et al. Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma. Cancer Immunol Immunother 70, 721–732 (2021). https://doi.org/10.1007/s00262-020-02713-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-020-02713-6

Keywords

Search

Navigation